No Data
No Data
Tianjin Lisheng Pharmaceutical's H1 Attributable Profit, Revenue Grow
Tianjin Dev (00882.HK): tianjin lisheng pharmaceutical's net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.
On August 23, Tianjin Development (00882.HK) announced that Tianjin Lisheng Pharmaceutical (002393.SZ) achieved revenue of 0.745 billion yuan (RMB) in the first half of 2024, a year-on-year increase of 13.25%; the net income attributable to shareholders of Tianjin Lisheng Pharmaceutical was 0.102 billion yuan, a year-on-year increase of 13.50%; and the basic earnings per share was 0.40 yuan.
Express News | Tianjin Development - Hy Total Operating Income for Tianjin Lisheng Pharmaceutical RMB744.6 Mln Vs RMB657.5 Mln
Express News | Tianjin Development Holdings Ltd - Hy Net Profit for Tianjin Lisheng Pharmaceutical of RMB101.3 Mln
TIANJIN DEV: Unaudited Financial Results for the six months ended 30 June 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.
Board of directors of Tianjin Dev (00882.HK) held a meeting on August 29 to consider and approve the mid-term performance.
Tianjin Dev (00882.HK) announced that it will hold a board of directors meeting on Thursday, August 29, 2024 to consider and approve, among other matters, the announcement of the Company and its subsidiaries' interim results for the six months ended June 30, 2024, and to consider the distribution of interim dividends (if any).
No Data